Creating Superior Approaches to the Treatment of Bleeding Disorders

The Company

Additional Information

The Company and the Technology

Sanguistat was formed in March 2016 by Ron Burch M.D., Ph.D. and licensed the Neural Tourniquet technology from Northwell Health in August 2016. The technology includes a robust portfolio of products, invented by Dr. Kevin Tracy from the Feinstein Institute for Medical Research. This technology addresses acute and chronic bleeding through the electrostimulation of the vagus nerve in the pinna of the ear. This stimulation primes platelets in the spleen which when they contact injured tissue become activated more rapidly than resting platelets, resulting in reduction of bleeding time and blood loss by half or more in animal models. The company also has partnered with the Global Good Fund (an affiliate of the Gates Foundation) for development of the technology in the developing world and has received a grant towards the development of this technology.

Clinical Development

The Company successfully completed a Phase 1 trial which assessed safety, tolerability, and platelet priming. A phase 2 pilot study to assess the reduction in bleeding following Caesarian section is being initiated. This will be followed by a proof of concept study in adults with hemophilia.

Our Technology

The Neural Tourniquet TM

The Neural TourniquetTM is a medical device that reduces bleeding due to child birth, trauma, and hemophilia.

The Neural Tourniquet delivers an electrical signal to the vagus nerve which travels to the spleen, resulting in the priming of blood platelets. When they come into contact with damaged tissue, primed platelets initiate clot formation more rapidly than unprimed platelets.

Acute Bleeding

Preclinical studies have shown that the Neural Tourniquet can reduce blood loss due to trauma by 50%

Chronic Bleeding

in hemophilia by 70% following a single treatment lasting only a few minutes.